From March 12 to 15, 2024, the 14th World Antibody-Drug Conjugate Conference (World ADC) was held in London, UK. Dr. Guitao Wang, Dean of the Coherent Biopharma Research Institute, was invited to attend the conference and delivered a keynote speech, sharing the development strategy of CBP-1008 in the field of gynecological oncology, once again demonstrating Coherent Biopharma ‘s strong capabilities in drug R&D and clinical strategy.
On March 14, in the Clinical Lessons session, Dr. Guitao Wang, Dean of the Coherent Biopharma Research Institute, gave a speech on the theme of “Novel Modality for Gynecological Cancer Treatment: Understanding of CBP-1008 Clinical Trials from a Pre-Clinical Perspective.” He detailed the development strategy of Coherent Biopharma’s first Bi-XDC product, CBP-1008, in the field of gynecological oncology, shared the successful experience of clinical trial strategy through drug design, which attracted high attention and active discussion from the participants.